Automated closed-cell production platform solves dilemma of industrial-scale manufacturing for mesenchymal stromal cell-based therapy

Mesenchymal stromal cells(MSCs),known for their therapeutic bioactivity,find widespread application as cellular drugs for treating various diseases.MSCs obtained from patients or donors require extensive large-scale expansion for clinical applications.However,the conventional method of cultivating MSCs involves several manual processes and yields inconsistent batch-to-batch quality.Consequently,it has not been scalable as a cell therapy[1].To overcome the limitations of conventional planar cell culture,van Wezel initially proposed a system for culturing cells in suspension using microcarriers and successfully proliferated rabbit embryonic skin cells and human embryonic lung cells[2].Subsequently,microcarrier technology has been employed across various pharmaceutical applications,leading to the development and commercialization of a diverse array of microcarriers with distinct physicochemical properties.